



Press Release

Source: CLX Investment Company

CLX Investment Company CEO Discusses Status of Zonda, Inc. Subsidiary

Issued Thursday, December 20, 9:00 am ET

MURRIETA, CA--(MARKET WIRE)--Dec. 20, 2007--CLX Investment Company, Inc. (OTC BB: CLXN), which owns 51% of Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for the medical and non-medical markets, today issued a statement from newly appointed president and chief executive officer, Vera Leonard, regarding the status of Zonda's business and strategic direction for this subsidiary.

“As we have discussed over the past two months, CLX management has developed and is executing a strategy that includes maximizing the potential of the Zonda subsidiary through regulatory approval and distribution of its diagnostic testing products in domestic and international markets, as well as the planned acquisition, licensing and distribution of additional innovative medical diagnostic technologies that are ideally suited for further development, regulatory approval and distribution in the United States. As evidenced by our experience at the 2007 MEDICA trade fair, we believe that there are significant opportunities to find these technologies and use CLX's internal capabilities and developing relationships to achieve the necessary U.S. regulatory approvals and begin selling in this market.

“When I was appointed as CEO of Zonda earlier this year, I immediately set out to determine the current status of the company's operations and to develop a strategy to maximize its future potential. As part of the due diligence process, it was discovered that a Zonda employee had, in the past, been subject to debarment by the FDA. However, the potential financial and humanitarian impact of this product, were it proven effective, was considered so significant that the decision was made to continue with the project. CLX did, however, require restructure within Zonda in order to continue its funding of the company. Because Zonda's application for FDA approval lacked the appropriate supporting clinical information, it became clear that the submission would ultimately need to be repackaged and a new application filed if FDA approvals were to be achieved. We secured the services of Safis Solutions, as announced recently, and now have a schedule for clinical trials with a planned FDA submission for the Zonda rapid test for *Chlamydia*.

“Sales of Zonda’s medical diagnostic testing product line in Europe were also extensively examined, and I used the MEDICA event to meet face to face with virtually all of Zonda’s European distributors. As a result of this due diligence, I came to the conclusion that Zonda’s current method of achieving sales in Europe is not as effective as it could be and that a new European strategy should be developed. We have progressed in that direction, and in the coming weeks, we expect to announce the details of this new strategy, which includes streamlining operations, minimizing costs, and better serving our customers in European markets.

“Our review of the patent on Zonda’s diagnostic testing procedures revealed that the patent application included insufficient information. Since that time, new patent attorneys have been retained under the sub-contractor agreement with Safis Solutions to shepherd the application through the patent approval process.

“All of these discoveries were clearly challenges that impacted the status of Zonda and may have impeded its potential future growth. Even with these issues considered, however, I came aboard as President/CEO of CLX with the belief that all of the issues could be effectively managed and, as discussed here, we have already taken tangible steps in that direction. The bottom line is that an accurate rapid medical diagnostic test for diseases such as *Chlamydia* would be a significantly valuable asset for a company, and we do believe that Zonda’s product has the potential to be that type of test.

“An ancillary benefit of the challenges presented by Zonda is that they led us to engage American Health Partners, who then retained Safis Solutions as a subcontractor, to help us examine the issues related to FDA submissions and patent protection. We now expect that the relationships we are developing with these two companies, as well as other consultants that may be retained in the future, will strengthen CLX’s capacity to identify and acquire, license and/or distribute additional medical diagnostic testing products.

“We hope that shareholders who continue to follow the developing story of Zonda and other projects CLX intends to pursue will share my enthusiasm about the future potential of this company.”

To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit <http://www.clxinvestments.com/email.php>.

About CLX Investment Company

CLX Investment Company (www.clxinvestments.com) holds a 51% equity interest in Zonda, Inc. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of “smart” scrolling advertising billboards.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments’ control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ

materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact:
Gemini Financial Communications
A. Beyer
951-677-8073
investors@clxinvestments.com